149 related articles for article (PubMed ID: 26137074)
1. Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay.
Zhang J; Li H
Oncol Lett; 2015 May; 9(5):2374-2380. PubMed ID: 26137074
[TBL] [Abstract][Full Text] [Related]
2. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
3. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract][Full Text] [Related]
4. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
5. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
6. Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ-based proteomics.
Wang Y; Li H
Oncol Lett; 2018 Jun; 15(6):9793-9801. PubMed ID: 29928353
[TBL] [Abstract][Full Text] [Related]
7. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
[TBL] [Abstract][Full Text] [Related]
8. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
[TBL] [Abstract][Full Text] [Related]
9. In vitro chemosensitivity in ovarian carcinoma: Comparison of three leading assays.
Tatar B; Boyraz G; Selçuk İ; Doğan AK; Usubütün A; Tuncer ZS
J Turk Ger Gynecol Assoc; 2016; 17(1):35-40. PubMed ID: 27026777
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA.
Chen Z; Zhang S; Ma S; Li C; Xu C; Shen Y; Zhao J; Miao L
Anticancer Agents Med Chem; 2018; 18(1):139-145. PubMed ID: 28425853
[TBL] [Abstract][Full Text] [Related]
12. [Application of ATP based bioluminescence tumor chemosensitivity assay in the chemotherapy of pediatric solid tumor].
Cheng HY; Zhu XD; Wang HM; Qin H
Zhonghua Er Ke Za Zhi; 2009 Aug; 47(8):598-603. PubMed ID: 19951493
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.
Cree IA; Neale MH; Myatt NE; de Takats PG; Hall P; Grant J; Kurbacher CM; Reinhold U; Neuber K; MacKie RM; Chana J; Weaver PC; Khoury GG; Sartori C; Andreotti PE
Anticancer Drugs; 1999 Jun; 10(5):437-44. PubMed ID: 10477162
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
17. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
Ling ZQ; Qi CJ; Lu XX; Qian LJ; Gu LH; Zheng ZG; Zhao Q; Wang S; Fang XH; Yang ZX; Yin J; Mao WM
Acta Pharmacol Sin; 2012 Mar; 33(3):401-6. PubMed ID: 22286916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
